Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden

BACKGROUND: Tolvaptan is the only vasopressin V(2) receptor antagonist licensed by the European Medicines Agency for the treatment of hyponatraemia (HN) secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). We have investigated the cost-effectiveness of tolvaptan versus...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Endocr Disord
Hlavní autoři: Jamookeeah, Clare, Robinson, Paul, O’Reilly, Karl, Lundberg, Johan, Gisby, Martin, Ländin, Michael, Skov, Jakob, Trueman, David
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2016
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4867540/
https://ncbi.nlm.nih.gov/pubmed/27184496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12902-016-0104-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky